Drugs / tNIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06485752 Comparator | Nov 2024 → Feb 2025 | COVID-19 | Novavax | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tNIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06485752 ↗ |
| Route | Intramuscular | “tNIV will be administered as a single 0.5 mL IM injection Day 0” NCT06485752 ↗ |